Valuation: Astellas Pharma Inc.

Market Cap 4,700B 29.6B 26.54B 24.46B 22.21B 42.04B 2,775B 43.22B 293B 117B 1,487B 111B 109B P/E 2027 *
12.2x
P/E 2028 * 12.6x
Enterprise Value 4,659B 29.34B 26.31B 24.25B 22.02B 41.68B 2,751B 42.84B 290B 116B 1,474B 110B 108B EV / Sales 2027 *
1.95x
EV / Sales 2028 * 1.9x
Free-Float
98.92%
Yield 2027 *
3.06%
Yield 2028 * 3.17%
1 day+1.05%
1 week+5.92%
Current month+3.01%
1 month+15.13%
3 months+12.42%
6 months+13.91%
Current year+26.54%
1 week 2,463.5
Extreme 2463.5
2,753
1 month 2,244
Extreme 2244
2,753
Current year 2,041
Extreme 2041
2,753
1 year 1,813.5
Extreme 1813.5
2,753
3 years 1,243.5
Extreme 1243.5
2,753
5 years 1,243.5
Extreme 1243.5
2,753
10 years 1,243.5
Extreme 1243.5
2,753
Manager TitleAgeSince
Chief Executive Officer 64 2023-02-09
Director of Finance/CFO 55 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 64 2019-05-31
Director/Board Member 59 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%+5.92%+47.92%+50.44% 29.3B
+1.44%+1.63%+48.17%+139.63% 1,258B
-0.47%+5.49%+49.03%+90.68% 679B
+0.20%+2.76%+34.37%+112.06% 518B
+0.17%+2.76%+44.07%+69.71% 390B
-0.48%+2.34%+70.66%+46.02% 367B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 293B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 210B
Average +0.08%+1.00%+41.99%+80.56% 430B
Weighted average by Cap. -0.08%+1.17%+43.69%+96.51%

Financials

2027 *2028 *
Net sales 2,385B 15.02B 13.47B 12.41B 11.27B 21.33B 1,408B 21.93B 149B 59.21B 754B 56.35B 55.16B 2,223B 14B 12.56B 11.57B 10.51B 19.89B 1,313B 20.44B 139B 55.2B 703B 52.55B 51.43B
Net income 380B 2.4B 2.15B 1.98B 1.8B 3.4B 225B 3.5B 23.71B 9.45B 120B 8.99B 8.8B 355B 2.24B 2.01B 1.85B 1.68B 3.18B 210B 3.27B 22.13B 8.82B 112B 8.39B 8.22B
Net Debt -40.41B -255M -228M -210M -191M -362M -23.86B -372M -2.52B -1B -12.78B -955M -935M -472B -2.97B -2.66B -2.45B -2.23B -4.22B -278B -4.34B -29.39B -11.71B -149B -11.15B -10.91B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-11-10 ¥2,645.00 +0.92% 1,440,200
26-11-10 ¥2,621.00 +1.49% 5,944,900
26-11-09 ¥2,582.50 +4.49% 5,169,000
26-11-06 ¥2,471.50 -7.52% 8,818,700
26-11-05 ¥2,672.50 +6.88% 10,576,300
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,621.00JPY
Average target price
2,582.86JPY
Spread / Average Target
-1.46%
  1. Stock Market
  2. Stocks
  3. 4503 Stock